Lindsey Shapiro, PhD,  science writer—

Implantation of the Aeson Total Artificial Heart — a device from Carmat designed to mimic the heart’s function — was able to help three advanced heart failure patients with pulmonary hypertension (PH) to become eligible for a heart transplant. The patients, who had previously been considered transplant-ineligible due…

Activation of an immune signaling molecule called STAT6 may lead to pulmonary hypertension (PH) in people with oxygen deprivation due to obstructive sleep apnea, according to a recent study in mice. Obstructive sleep apnea is a common sleep disorder characterized by chronic intermittent hypoxia, or repeated episodes of stopping…

An artificial intelligence (AI)-based algorithm is capable of detecting features of pulmonary hypertension (PH) by analyzing heart sounds recorded with a digital stethoscope, a study found. Eko Health developed the technology with the help of a $2.7 million National Institutes of Health (NIH) grant. The algorithm could…

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…

Elevated blood levels of an inflammatory biomarker called the neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of death among people with pulmonary hypertension (PH) related to chronic kidney disease (CKD), according to a recent report. “NLR, which is a convenient and inexpensive parameter, may be a novel…

Most adults with pulmonary arterial hypertension (PAH) who switched to Uptravi (selexipag) from other medications in its class achieved stabilization or a lessening of disease severity, according to an analysis of real-world treatment data from the SPHERE registry. Clinical outcomes were also generally good for Uptravi-treated PAH patients…

Cereno Scientific‘s investigational therapy CS1 was well tolerated and showed signs of clinical benefit in people with pulmonary arterial hypertension (PAH), according to top-line data from a Phase 2a clinical trial. The company plans to start discussions with regulatory authorities and will pursue a pivotal clinical trial to…

A global clinical trial evaluating a pulmonary artery denervation (PADN) device in people with pulmonary hypertension (PH) associated with left heart disease has launched in Europe, with the first two patients enrolled at a hospital in Portugal, Pulnovo Medical, the device’s developer, announced. These two adults have undergone…

An advisory committee of the European Medicines Agency (EMA) is recommending that Winrevair (sotatercept) be approved for the treatment of pulmonary arterial hypertension (PAH) in the Europe Union. Specifically, the Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending that Winrevair to be used in…

Pulmonary arterial hypertension (PAH) patients enrolled in a Phase 2b clinical trial testing AV-101, an inhaled formulation of imatinib, entered the trial with significant disease despite use of triple background therapy, according to data shared by developer Aerovate Therapeutics. The company said the study population will allow for…

AER-901, a new inhaled formulation of imatinib delivered via a specialized device, was predicted to reach 2-3 times higher levels in the lung tissue over standard inhalers among people with forms of pulmonary hypertension (PH), according to new data from Aerami Therapeutics, its developer. Having been proven to…

Researchers have identified two inflammation-related genes — SELE and CCL20 — whose activity could serve as diagnostic biomarkers for the development of pulmonary hypertension (PH) in people with COVID-19. Further, the team also identified molecules that target these biomarkers as possible therapeutic approaches for managing the complication. Overall, the…